Spero Therapeutics, Inc

(NASDAQ:SPRO)

Latest On Spero Therapeutics, Inc (SPRO):

Date/Time Type Description Signal Details
2023-05-12 00:52 ESTNewsSpero Therapeutics GAAP EPS of -$0.25 beats by $0.08, revenue of $2.07M beats by $0.8MN/A
2023-05-12 00:51 ESTNewsSpero Therapeutics, Inc. (SPRO) Q1 2023 Earnings Call TranscriptN/A
2023-05-10 20:41 ESTNewsSpero Therapeutics Q1 2023 Earnings PreviewN/A
2023-04-22 00:37 ESTNewsSpero Therapeutics: Massive Partnership Deal Still Not Properly Valued By The MarketN/A
2023-03-31 10:33 ESTNewsSpero Therapeutics GAAP EPS of $0.55 beats by $0.51, revenue of $47.44M beats by $24.57MN/A
2023-03-31 10:33 ESTNewsSpero Therapeutics, Inc. (SPRO) Q4 2022 Earnings Call TranscriptN/A
2023-03-13 03:53 ESTNewsSpero Therapeutics Q4 2022 Earnings PreviewN/A
2022-11-15 07:59 ESTNewsSpero Therapeutics GAAP EPS of -$0.33 misses by $0.03, revenue of $2M misses by $3.42MN/A
2022-11-15 07:59 ESTNewsSpero Therapeutics, Inc. (SPRO) Q3 2022 Earnings Call TranscriptN/A
2022-11-12 11:25 ESTNewsSpero Therapeutics Q3 2022 Earnings PreviewN/A
2022-10-03 16:29 ESTNewsSpero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder ValueN/A
2022-09-22 06:48 ESTNewsSpero stock soars 79% as GSK to pick stake under license deal for UTI antibioticN/A
2022-09-15 22:23 ESTNewsSpero Therapeutics appoints Kamal Hamed MD CMON/A
2022-09-07 07:24 ESTNewsSpero jumps 64% as FDA clarifies future regulatory path for UTI candidateN/A
2022-08-12 08:06 ESTNewsSpero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-10 23:40 ESTNewsSpero Therapeutics GAAP EPS of -$0.87, revenue of $1.99MN/A
2022-06-28 10:10 ESTNewsFDA rejects Spero's application seeking approval of its urinary tract infection tabletsN/A
2022-05-17 17:21 ESTNewsSpero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-16 19:16 ESTNewsSpero Therapeutics GAAP EPS of -$1.01 misses by $0.08, revenue of $2.07M beats by $0.14MN/A
2022-05-16 02:24 ESTNewsSpero Therapeutics Q1 2022 Earnings PreviewN/A
2022-05-04 12:34 ESTNewsSpero downgraded at Cowen after regulatory setback to lead assetN/A
2022-05-03 20:42 ESTNewsSpero stock crashes 70% on potential FDA rejection of uti drug tebipenem; to cut workforce by ~75%N/A
2022-04-18 20:38 ESTNewsSpero Therapeutics stock dips after PT cut to $37 at H.C. Wainwright on pending approval of tebipenem HBrN/A
2022-04-01 12:23 ESTNewsSpero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q4 2021 Results - Earnings Call TranscriptN/A
2022-04-01 12:23 ESTNewsSpero Therapeutics slips after FDA feedback on antibacterial therapyN/A
2022-03-31 18:25 ESTNewsSpero Therapeutics GAAP EPS of -$0.90 misses by $0.15, revenue of $2.74M misses by $2.21MN/A
2022-02-17 03:46 ESTNewsSpero Therapeutics antibiotic SPR206 shows promise in phase 1 trialN/A
2022-01-19 17:56 ESTNewsSpero granted up to $12.9M by BARDA to develop urinary tract infection drug for childrenN/A
2022-01-04 18:28 ESTNewsFDA lifts clinical hold on Spero's mid-stage SPR720 trial in nontuberculous mycobacterialN/A
2022-01-03 09:48 ESTNewsSpero gets FDA priority review for oral tebipenem HBr to treat urinary tract infectionsN/A
2021-11-11 13:22 ESTNewsSpero Therapeutics EPS misses by $0.04, misses on revenueN/A
2021-11-11 13:22 ESTNewsSpero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-10 16:04 ESTNewsSpero Therapeutics Q3 2021 Earnings PreviewN/A
2021-10-29 05:35 ESTNewsSpero Therapeutics submits tebipenem NDA for treatment of complicated urinary tract infectionsN/A
2021-10-15 20:49 ESTNewsSizing Up Spero TherapeuticsN/A
2021-10-01 21:44 ESTNewsSpero Therapeutics shares fall on Oppenheimer downgradeN/A
2021-08-17 01:01 ESTNewsSpero Therapeutics, Inc. 2021 Q2 - Results - Earnings Call PresentationN/A
2021-08-08 01:05 ESTNewsSpero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-06 10:52 ESTNewsSpero Therapeutics EPS beats by $0.12, beats on revenueN/A
2021-07-22 01:45 ESTNewsSpero Therapeutics initiates two early-stage trials for SPR206N/A
2021-07-22 01:29 ESTNewsSpero Therapeutics stock gains on $40M equity investment from Pfizer and licensing agreement for SPR206N/A
2021-07-22 01:15 ESTNewsSpero Therapeutics (SPRO) Presents At Ladenburg Thalmann Healthcare Conference - SlideshowN/A
2021-05-06 19:23 ESTNewsSpero Therapeutics EPS misses by $0.01, beats on revenueN/A
2021-03-24 06:25 ESTNewsSpero Therapeutics (SPRO) Presents At Oppenheimer 31st Annual Healthcare Conference - SlideshowN/A
2021-03-16 22:05 ESTAnalyst RatingThe Analyst Target Price has increased from $32.88 to $33.Buy
2021-03-12 11:34 ESTNewsSpero Therapeutics EPS beats by $0.06, misses on revenueN/A
2021-03-12 11:34 ESTNewsSpero Therapeutics' (SPRO) CEO Ankit Mahadevia on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-12 08:35 ESTFinancialsCompany financials have been released.Neutral
2021-03-12 04:43 ESTEarnings EstimateAn EPS average of -$3.81 is estimated for the 2022 year.Sell
2021-03-12 04:43 ESTEarnings EstimateAn EPS average of -$0.86 is estimated for the quarter ending on June 30, 2021.Sell

About Spero Therapeutics, Inc (SPRO):

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

See Advanced Chart

General

  • Name Spero Therapeutics, Inc
  • Symbol SPRO
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 89
  • Fiscal Year EndDecember
  • IPO Date2017-11-02
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://sperotherapeutics.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 40.38
  • Price/Book (Most Recent Quarter) 3.76
  • Enterprise Value Revenue 40.46
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.82
  • Next Year EPS Estimate -$3.02
  • Next Quarter EPS Estimate -$0.80
  • Operating Margin -848%
  • Return on Assets -38%
  • Return on Equity -76%
  • Revenue 9.33 million
  • Earnings Per Share -$2.24
  • Revenue Per Share $0.42
  • Gross Profit -57673000
  • Quarterly Earnings Growth -47.5%
View More

Highlights

  • Market Capitalization 485.05 million
  • EBITDA -40775000
  • Analyst Target Price $33
  • Book Value Per Share $4.51
View More

Share Statistics

  • Shares Outstanding 29.5 million
  • Shares Float 21.6 million
  • % Held by Insiders 1081%
  • % Held by Institutions 60.98%
  • Shares Short 2.2 million
  • Shares Short Prior Month 2.24 million
  • Short Ratio 6.89
  • Short % of Float 9%
  • Short % of Shares Outstanding 8%
View More

Technicals

  • Beta 1.67
  • 52 Week High $23.64
  • 52 Week Low $5.51
  • 50 Day Moving Average 18.65
  • 200 Day Moving Average 15.69
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Spero Therapeutics, Inc (SPRO) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Spero Therapeutics, Inc (SPRO) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-11$1.91 million-$0.68-$0.748.36%
2020-09-302020-11-05$N/A-$0.86-$0.892.93%
2020-06-302020-08-06$N/A-$0.85-$1.1324.78%
2020-03-312020-05-08$N/A-$1.22-$1.3811.43%
2019-12-312020-03-16$3.63 million-$1.36-$1.08-25.46%
2019-09-302019-11-04$4.64 million-$0.95-$0.85-12.2%
2019-06-302019-08-08$2.16 million-$0.74-$0.8613.95%
2019-03-312019-05-09$7.72 million-$0.29-$0.7762.34%
2018-12-312019-03-14$1.69 million-$0.60-$0.7519.57%
2018-09-302018-11-08$658000-$0.60-$0.634.76%
2018-06-302018-08-09$463000-$0.69-$0.7810.97%
2018-03-312018-05-10$1.15 million-$0.74-$1.2038.33%
2017-09-302017-12-14$597000-$36.02-$35.07-2.72%

Spero Therapeutics, Inc (SPRO) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Spero Therapeutics, Inc (SPRO) Chart:

Spero Therapeutics, Inc (SPRO) News:

Below you will find a list of latest news for Spero Therapeutics, Inc (SPRO) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Spero Therapeutics, Inc (SPRO) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-06-212.50.05CALL0 1540FALSE00
2024-06-2150CALL0 00FALSE00
2024-06-217.50CALL0 00FALSE00
2024-06-212.50PUT0 00TRUE00
2024-06-2150PUT0 01464.87TRUE00
2024-06-217.50PUT0 00TRUE00
2024-07-192.50.05CALL0 6290FALSE00
2024-07-1950.14CALL0 40FALSE00
2024-07-197.50CALL0 00FALSE00
2024-07-192.51PUT0 120TRUE00
2024-07-1950PUT0 0635.82TRUE00
2024-07-197.50PUT0 0847.78TRUE00
2024-10-182.50.05CALL0 97153.27FALSE00
2024-10-1850.2CALL0 10FALSE00
2024-10-187.50CALL0 00FALSE00
2024-10-182.50PUT0 096.26TRUE00
2024-10-1850PUT0 0334.64TRUE00
2024-10-187.50PUT0 0227.24TRUE00
2025-01-172.50.25CALL0 22128.14FALSE00
2025-01-1750.1CALL0 10FALSE00
2025-01-177.50CALL0 00FALSE00
2025-01-172.50PUT0 00TRUE00
2025-01-1750PUT0 0290.25TRUE00
2025-01-177.50PUT0 0355.14TRUE00

Latest SPRO Trades:

Date Shares Price
Jun 13, 2022 7:58 PM EST9$1.015
Jun 13, 2022 7:58 PM EST38$1.015
Jun 13, 2022 7:58 PM EST15$1.015
Jun 13, 2022 7:58 PM EST26$1.015
Jun 13, 2022 7:59 PM EST100$1.02

Spero Therapeutics, Inc (SPRO) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/0001209191-20-039352-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1701108/000031506619001334/0000315066-19-001334-index.htm
2018-06-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924318015325/0000899243-18-015325-index.htm
2018-06-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924318015326/0000899243-18-015326-index.htm
2018-06-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924318015327/0000899243-18-015327-index.htm
2018-06-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924318015328/0000899243-18-015328-index.htm
2018-06-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924318015329/0000899243-18-015329-index.htm
2018-06-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924318015330/0000899243-18-015330-index.htm
2018-07-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/0000899243-18-019566-index.htm
2018-07-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924318019567/0000899243-18-019567-index.htm
2018-07-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924318019568/0000899243-18-019568-index.htm
2018-09-213Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924318025017/0000899243-18-025017-index.htm
2018-09-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924318025024/0000899243-18-025024-index.htm
2019-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924319000175/0000899243-19-000175-index.htm
2019-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924319000178/0000899243-19-000178-index.htm
2019-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924319000179/0000899243-19-000179-index.htm
2019-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924319000181/0000899243-19-000181-index.htm
2019-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924319000183/0000899243-19-000183-index.htm
2019-03-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924319008360/0000899243-19-008360-index.htm
2019-03-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924319009318/0000899243-19-009318-index.htm
2019-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924319015663/0000899243-19-015663-index.htm
2019-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924319015665/0000899243-19-015665-index.htm
2019-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924319015667/0000899243-19-015667-index.htm
2019-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924319015668/0000899243-19-015668-index.htm
2019-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924319015672/0000899243-19-015672-index.htm
2019-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924319015673/0000899243-19-015673-index.htm
2019-11-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924319026993/0000899243-19-026993-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924320000625/0000899243-20-000625-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924320000628/0000899243-20-000628-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924320000629/0000899243-20-000629-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924320000631/0000899243-20-000631-index.htm
2020-01-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924320001061/0000899243-20-001061-index.htm
2020-02-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924320002604/0000899243-20-002604-index.htm
2020-02-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924320002616/0000899243-20-002616-index.htm
2020-02-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924320002617/0000899243-20-002617-index.htm
2020-02-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924320002618/0000899243-20-002618-index.htm
2020-04-233Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924320011244/0000899243-20-011244-index.htm
2020-06-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924320017496/0000899243-20-017496-index.htm
2020-07-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924320018847/0000899243-20-018847-index.htm
2020-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924320024865/0000899243-20-024865-index.htm
2020-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924320028430/0000899243-20-028430-index.htm
2020-10-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924320029326/0000899243-20-029326-index.htm
2020-10-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924320029327/0000899243-20-029327-index.htm
2020-10-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924320029328/0000899243-20-029328-index.htm
2020-10-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924320029329/0000899243-20-029329-index.htm
2020-10-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924320029333/0000899243-20-029333-index.htm
2020-10-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924320029334/0000899243-20-029334-index.htm
2020-10-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924320029337/0000899243-20-029337-index.htm
2020-10-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924320029338/0000899243-20-029338-index.htm
2020-11-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000089924320030490/0000899243-20-030490-index.htm
2018-07-17SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1701108/000090342318000399/0000903423-18-000399-index.htm
2018-07-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000090342318000400/0000903423-18-000400-index.htm
2018-09-19SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1701108/000090342318000513/0000903423-18-000513-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1701108/000092189519000484/0000921895-19-000484-index.htm
2018-05-25DRSDraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1701108/000095012318005976/0000950123-18-005976-index.htm
2019-02-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1701108/000110465919006432/0001104659-19-006432-index.htm
2020-02-04SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1701108/000110465920010526/0001104659-20-010526-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1701108/000114420419008281/0001144204-19-008281-index.htm
2018-04-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312518104993/0001193125-18-104993-index.htm
2018-04-27DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1701108/000119312518136751/0001193125-18-136751-index.htm
2018-05-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312518159225/0001193125-18-159225-index.htm
2018-06-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312518188029/0001193125-18-188029-index.htm
2018-07-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312518214220/0001193125-18-214220-index.htm
2018-07-09S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1701108/000119312518214717/0001193125-18-214717-index.htm
2018-07-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312518214735/0001193125-18-214735-index.htm
2018-07-11S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1701108/000119312518216210/0001193125-18-216210-index.htm
2018-07-13424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1701108/000119312518217909/0001193125-18-217909-index.htm
2018-07-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312518218281/0001193125-18-218281-index.htm
2018-07-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312518219722/0001193125-18-219722-index.htm
2018-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312518244366/0001193125-18-244366-index.htm
2018-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312518247901/0001193125-18-247901-index.htm
2018-09-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312518285631/0001193125-18-285631-index.htm
2018-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312518322565/0001193125-18-322565-index.htm
2018-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312518324949/0001193125-18-324949-index.htm
2018-11-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312518328530/0001193125-18-328530-index.htm
2018-12-03S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1701108/000119312518341227/0001193125-18-341227-index.htm
2018-12-07CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1701108/000119312518344890/0001193125-18-344890-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312519003882/0001193125-19-003882-index.htm
2019-03-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312519074792/0001193125-19-074792-index.htm
2019-03-14S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1701108/000119312519074902/0001193125-19-074902-index.htm
2019-03-14S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1701108/000119312519074912/0001193125-19-074912-index.htm
2019-03-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312519078993/0001193125-19-078993-index.htm
2019-03-298-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312519092830/0001193125-19-092830-index.htm
2019-04-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312519111025/0001193125-19-111025-index.htm
2019-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1701108/000119312519122422/0001193125-19-122422-index.htm
2019-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312519142982/0001193125-19-142982-index.htm
2019-06-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312519167255/0001193125-19-167255-index.htm
2019-06-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312519171876/0001193125-19-171876-index.htm
2019-06-14424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1701108/000119312519172777/0001193125-19-172777-index.htm
2019-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312519216834/0001193125-19-216834-index.htm
2019-09-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312519239450/0001193125-19-239450-index.htm
2019-10-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312519261358/0001193125-19-261358-index.htm
2019-11-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312519283355/0001193125-19-283355-index.htm
2019-12-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312519306821/0001193125-19-306821-index.htm
2019-12-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312519319256/0001193125-19-319256-index.htm
2020-01-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312520019086/0001193125-20-019086-index.htm
2020-01-31SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1701108/000119312520021361/0001193125-20-021361-index.htm
2020-02-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1701108/000119312520030568/0001193125-20-030568-index.htm
2020-02-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312520030705/0001193125-20-030705-index.htm
2020-02-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312520056529/0001193125-20-056529-index.htm
2020-03-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312520073981/0001193125-20-073981-index.htm
2020-03-19S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1701108/000119312520079102/0001193125-20-079102-index.htm
2020-04-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312520108749/0001193125-20-108749-index.htm
2020-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312520137009/0001193125-20-137009-index.htm
2020-05-118-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312520139200/0001193125-20-139200-index.htm
2020-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312520160206/0001193125-20-160206-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312520211931/0001193125-20-211931-index.htm
2020-08-06S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1701108/000119312520211997/0001193125-20-211997-index.htm
2020-09-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312520240546/0001193125-20-240546-index.htm
2020-09-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312520242243/0001193125-20-242243-index.htm
2020-09-09424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1701108/000119312520242277/0001193125-20-242277-index.htm
2020-09-14424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1701108/000119312520244773/0001193125-20-244773-index.htm
2020-09-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312520244804/0001193125-20-244804-index.htm
2020-09-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312520246775/0001193125-20-246775-index.htm
2020-09-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1701108/000119312520259653/0001193125-20-259653-index.htm
2020-10-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312520279790/0001193125-20-279790-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1701108/000119312520286841/0001193125-20-286841-index.htm
2020-02-18SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1701108/000119380520000223/0001193805-20-000223-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/0001209191-20-039352-index.htm
2020-02-14SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1701108/000138713120001836/0001387131-20-001836-index.htm
2020-06-04SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1701108/000138713120005474/0001387131-20-005474-index.htm
2018-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1701108/000156459018012933/0001564590-18-012933-index.htm
2018-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1701108/000156459018021018/0001564590-18-021018-index.htm
2018-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1701108/000156459018028526/0001564590-18-028526-index.htm
2019-03-1410-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1701108/000156459019007805/0001564590-19-007805-index.htm
2019-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1701108/000156459019017941/0001564590-19-017941-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1701108/000156459019030746/0001564590-19-030746-index.htm
2019-11-0410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1701108/000156459019039770/0001564590-19-039770-index.htm
2020-03-1610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1701108/000156459020010998/0001564590-20-010998-index.htm
2020-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1701108/000156459020023243/0001564590-20-023243-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1701108/000156459020037710/0001564590-20-037710-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1701108/000156459020051279/0001564590-20-051279-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1701108/000159198619000004/0001591986-19-000004-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1701108/000159198620000005/0001591986-20-000005-index.htm
2020-09-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000159198620000013/0001591986-20-000013-index.htm
2020-09-23SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1701108/000159198620000014/0001591986-20-000014-index.htm
2020-11-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1701108/000159198620000015/0001591986-20-000015-index.htm
2018-07-12EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1701108/999999999518001785/9999999995-18-001785-index.htm
2018-12-11EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1701108/999999999518003105/9999999995-18-003105-index.htm
2018-12-11CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1701108/999999999718009412/9999999997-18-009412-index.htm
2019-04-01CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1701108/999999999719002232/9999999997-19-002232-index.htm

Spero Therapeutics, Inc (SPRO) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Spero Therapeutics, Inc (SPRO). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1081%
Institutional Ownership: 6098%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-07-05Cristina LarkinChief Operating OfficerSell4,000.0017.5070,000.001,500.00https://www.sec.gov/Archives/edgar/data/1701108/000089924318019568/0000899243-18-019568-index.htm
2018-07-05Joel SendekChief Financial OfficerSell2,000.0017.5035,000.0015,181.00https://www.sec.gov/Archives/edgar/data/1701108/000089924318019567/0000899243-18-019567-index.htm
2018-07-05Joel SendekChief Financial OfficerBuy2,000.005.9011,800.0017,181.00https://www.sec.gov/Archives/edgar/data/1701108/000089924318019567/0000899243-18-019567-index.htm
2018-07-17PLC GLAXOSMITHKLINE10% Share HolderBuy80,000.0012.501,000,000.001,934,006.00https://www.sec.gov/Archives/edgar/data/1701108/000090342318000400/0000903423-18-000400-index.htm
2020-11-06Aquilo Capital Management, LLC10% Share HolderSell5,000.0013.7768,873.504,323,042.00https://www.sec.gov/Archives/edgar/data/1701108/000159198620000015/0001591986-20-000015-index.htm
2020-11-05Aquilo Capital Management, LLC10% Share HolderSell96,600.0013.981,350,332.764,328,042.00https://www.sec.gov/Archives/edgar/data/1701108/000159198620000015/0001591986-20-000015-index.htm
2020-11-04Aquilo Capital Management, LLC10% Share HolderSell72,500.0014.261,033,741.254,424,642.00https://www.sec.gov/Archives/edgar/data/1701108/000159198620000015/0001591986-20-000015-index.htm
2018-07-05Cristina LarkinChief Operating OfficerBuy4,000.005.9023,600.005,500.00https://www.sec.gov/Archives/edgar/data/1701108/000089924318019568/0000899243-18-019568-index.htm
2018-07-05Ankit MahadeviaOfficerSell3,076.0017.6254,203.7365,817.00https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/0000899243-18-019566-index.htm
2018-07-06Ankit MahadeviaOfficerSell200.0017.923,584.0065,817.00https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/0000899243-18-019566-index.htm
2020-06-22Ankit MahadeviaCEO and PresidentSell2,613.0014.3037,364.8565,817.00https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/0001209191-20-039352-index.htm
2020-06-23Ankit MahadeviaCEO and PresidentSell8,045.0014.33115,263.9365,817.00https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/0001209191-20-039352-index.htm
2020-06-24Ankit MahadeviaCEO and PresidentSell3,880.0014.2855,419.5965,817.00https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/0001209191-20-039352-index.htm
2020-06-25Ankit MahadeviaCEO and PresidentSell2,642.0014.2537,650.3565,817.00https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/0001209191-20-039352-index.htm
2020-07-07Ankit MahadeviaCEO and PresidentSell754.0014.2510,744.9565,817.00https://www.sec.gov/Archives/edgar/data/1701108/000089924320018847/0000899243-20-018847-index.htm
2020-07-09Ankit MahadeviaCEO and PresidentSell2,293.0014.3132,806.6465,817.00https://www.sec.gov/Archives/edgar/data/1701108/000089924320018847/0000899243-20-018847-index.htm
2020-09-08Ankit MahadeviaCEO and PresidentSell774.0014.2511,029.7365,817.00https://www.sec.gov/Archives/edgar/data/1701108/000089924320024865/0000899243-20-024865-index.htm
2020-10-13Ankit MahadeviaCEO and PresidentSell14,367.0014.28205,212.4865,817.00https://www.sec.gov/Archives/edgar/data/1701108/000089924320028430/0000899243-20-028430-index.htm
2020-10-14Ankit MahadeviaCEO and PresidentSell105.0014.251,496.2565,817.00https://www.sec.gov/Archives/edgar/data/1701108/000089924320028430/0000899243-20-028430-index.htm
2020-10-23Ankit MahadeviaCEO and PresidentSell20.0014.25285.0065,817.00https://www.sec.gov/Archives/edgar/data/1701108/000089924320029328/0000899243-20-029328-index.htm
2020-11-03Ankit MahadeviaCEO and PresidentSell2,137.0014.2730,489.6565,817.00https://www.sec.gov/Archives/edgar/data/1701108/000089924320030490/0000899243-20-030490-index.htm
2020-11-04Ankit MahadeviaCEO and PresidentSell7,370.0014.43106,335.1065,817.00https://www.sec.gov/Archives/edgar/data/1701108/000089924320030490/0000899243-20-030490-index.htm
2020-10-23Ankit MahadeviaCEO and PresidentBuy20.005.90118.0065,837.00https://www.sec.gov/Archives/edgar/data/1701108/000089924320029328/0000899243-20-029328-index.htm
2020-10-14Ankit MahadeviaCEO and PresidentBuy105.005.90619.5065,922.00https://www.sec.gov/Archives/edgar/data/1701108/000089924320028430/0000899243-20-028430-index.htm
2018-07-06Ankit MahadeviaOfficerSell200.0017.903,580.0066,017.00https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/0000899243-18-019566-index.htm
2018-07-06Ankit MahadeviaOfficerSell100.0017.711,770.5066,217.00https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/0000899243-18-019566-index.htm
2018-07-06Ankit MahadeviaOfficerSell100.0017.621,762.0066,317.00https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/0000899243-18-019566-index.htm
2018-07-06Ankit MahadeviaOfficerSell400.0017.587,032.0066,417.00https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/0000899243-18-019566-index.htm
2020-07-07Ankit MahadeviaCEO and PresidentBuy754.005.904,448.6066,571.00https://www.sec.gov/Archives/edgar/data/1701108/000089924320018847/0000899243-20-018847-index.htm
2020-09-08Ankit MahadeviaCEO and PresidentBuy774.005.904,566.6066,591.00https://www.sec.gov/Archives/edgar/data/1701108/000089924320024865/0000899243-20-024865-index.htm
2018-07-06Ankit MahadeviaOfficerSell100.0017.551,754.5066,817.00https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/0000899243-18-019566-index.htm
2018-07-06Ankit MahadeviaOfficerSell500.0017.508,750.0066,917.00https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/0000899243-18-019566-index.htm
2018-07-06Ankit MahadeviaOfficerBuy1,600.005.909,440.0067,417.00https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/0000899243-18-019566-index.htm
2020-11-03Ankit MahadeviaCEO and PresidentBuy2,137.005.9012,608.3067,954.00https://www.sec.gov/Archives/edgar/data/1701108/000089924320030490/0000899243-20-030490-index.htm
2020-07-09Ankit MahadeviaCEO and PresidentBuy2,293.005.9013,528.7068,110.00https://www.sec.gov/Archives/edgar/data/1701108/000089924320018847/0000899243-20-018847-index.htm
2020-06-22Ankit MahadeviaCEO and PresidentBuy2,613.005.9015,416.7068,430.00https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/0001209191-20-039352-index.htm
2020-06-25Ankit MahadeviaCEO and PresidentBuy2,642.005.9015,587.8068,459.00https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/0001209191-20-039352-index.htm
2018-07-05Ankit MahadeviaOfficerBuy3,076.005.9018,148.4068,893.00https://www.sec.gov/Archives/edgar/data/1701108/000089924318019566/0000899243-18-019566-index.htm
2020-06-24Ankit MahadeviaCEO and PresidentBuy3,880.005.9022,892.0069,697.00https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/0001209191-20-039352-index.htm
2020-11-04Ankit MahadeviaCEO and PresidentBuy7,370.005.9043,483.0073,187.00https://www.sec.gov/Archives/edgar/data/1701108/000089924320030490/0000899243-20-030490-index.htm
2020-06-23Ankit MahadeviaCEO and PresidentBuy8,045.005.9047,465.5073,862.00https://www.sec.gov/Archives/edgar/data/1701108/000120919120039352/0001209191-20-039352-index.htm
2020-10-13Ankit MahadeviaCEO and PresidentBuy14,367.005.9084,765.3080,184.00https://www.sec.gov/Archives/edgar/data/1701108/000089924320028430/0000899243-20-028430-index.htm